MOTS-c, Epitalon, SS-31, Humanin, and FOXO4-DRI: What the Research Actually Shows

What Is MOTS-c and Why Do Researchers Study It?

MOTS-c is a 16-amino-acid peptide encoded entirely within the mitochondrial genome, specifically the 12S rRNA region. Its discovery in 2015 by Lee and colleagues reclassified mitochondrial DNA as a source of bioactive signaling molecules, not merely a blueprint for respiratory-chain proteins. In male mice, a single injection activated AMPK in skeletal muscle and improved insulin sensitivity within 72 hours. The peptide circulates in human blood, declines with age, and drops further in people with type 2 diabetes.

Research interest centers on three overlapping areas: metabolic regulation, exercise mimicry, and aging biology. A 2015 Cell Metabolism study (N=animal cohorts) found that MOTS-c injection into diet-induced obese mice reduced body weight by roughly 7% over four weeks without altering food intake, an effect attributed to AMPK-driven fatty-acid oxidation in skeletal muscle [1]. A 2021 paper in Nature Aging reported that circulating MOTS-c levels in centenarians (N=70, mean age 107) were significantly higher than in 70-year-old controls, suggesting a possible association with exceptional longevity [2]. Neither finding establishes causation in humans, and no randomized controlled trial of MOTS-c has been published.

Mechanistically, MOTS-c translocates to the nucleus under metabolic stress, where it modulates gene expression through the antioxidant response element pathway [3]. This nuclear translocation distinguishes it from most peptide hormones. Clinicians reviewing the preclinical literature should note that effective rodent doses (roughly 5 mg/kg intraperitoneal) do not translate directly to human equivalents by simple weight scaling.

How Epitalon May Influence Telomere Biology

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from epithalamin, a pineal-gland extract studied in Soviet and Russian longevity research beginning in the 1970s. Its primary proposed mechanism is activation of telomerase, the enzyme that rebuilds telomeric DNA repeats lost during cell division.

A 2003 study by Khavinson and colleagues published in Bulletin of Experimental Biology and Medicine reported telomere lengthening in cultured human fetal fibroblasts treated with Epitalon, with treated cells reaching 44 population doublings versus 34 in untreated controls [4]. The same group published rodent lifespan data showing a 13-16% increase in mean lifespan in female SHR mice [5]. These findings have not been independently replicated in peer-reviewed human trials registered at ClinicalTrials.gov as of January 2025.

Epitalon also appears to influence melatonin secretion. A 2012 paper in the Annals of the New York Academy of Sciences noted that epithalamin extract restored nocturnal melatonin peaks in elderly women whose rhythm had flattened, though the sample size was small (N=14) [6]. If Epitalon shares this property, sleep-quality improvements sometimes reported anecdotally may have a plausible biological basis, even if the magnitude is unknown.

The regulatory picture is unambiguous. Epitalon is not approved by the FDA and does not appear on any DEA schedule. The FDA's 2023 guidance placing several peptides on the Category 2 list of substances that cannot be compounded does not specifically name Epitalon, but the agency's broader stance requires that any compounded drug meet the criteria of 503A or 503B pharmacy exemptions [7]. Physicians prescribing Epitalon off any formulary carry the full burden of informed-consent documentation.

SS-31: Targeting the Inner Mitochondrial Membrane

SS-31 (also called elamipretide, MTP-131, or Bendavia) is a four-amino-acid aromatic-cationic peptide that preferentially accumulates at the inner mitochondrial membrane, where it binds cardiolipin [8]. Cardiolipin is a phospholipid essential for maintaining the cristae architecture that houses the electron-transport chain. In aged mitochondria, cardiolipin content falls and cristae become disorganized, reducing ATP output per oxygen consumed.

SS-31 is the most clinically advanced peptide on this list. Stealth BioTherapeutics completed a Phase II trial (MMPOWER-3, N=218) in patients with primary mitochondrial myopathy. The trial did not meet its primary endpoint of improvement in the 6-minute walk distance at 36 weeks compared with placebo (mean difference 0.68 m, P=0.93) [9]. That result is a meaningful signal for clinicians: a mechanism with strong preclinical support can still fail in a rigorous human trial.

Positive signals do exist in smaller studies. A 2020 crossover trial (N=11) in older adults with heart failure with preserved ejection fraction (HFpEF) found that a single intravenous infusion of elamipretide improved peak mitochondrial ATP production capacity by 33% versus placebo, measured by phosphorus magnetic resonance spectroscopy [10]. The trial was sponsored by Stealth BioTherapeutics and published in JACC: Basic to Translational Science. Effect size was notable, but the sample was tiny and the duration was a single infusion.

Preclinical data from aged beagles showed that 28 days of subcutaneous SS-31 (0.5 mg/kg/day) improved left ventricular ejection fraction by 5.4 percentage points and reduced mitochondrial H2O2 production in cardiac tissue [11]. Dog-to-human translation is imperfect, but the cardiac-focused findings informed the HFpEF trial design. SS-31 is not FDA-approved. Elamipretide's new drug application was not filed following the MMPOWER-3 result.

Humanin: The Cytoprotective Mitochondrial Peptide

Humanin is a 21-amino-acid peptide also encoded within mitochondrial 16S rRNA. It was identified in 2001 by Hashimoto and colleagues while screening for factors that protect neurons from amyloid-beta toxicity in Alzheimer's disease models [12]. The name was chosen because the original cDNA clone rescued human neurons from death. Like MOTS-c, humanin levels decline measurably with age and are lower in people with insulin resistance.

The protective effects described in cell and rodent studies span several cell types. In neuronal cultures, nanomolar concentrations of humanin blocked apoptosis triggered by familial Alzheimer's disease gene mutants, amyloid-beta peptide, and oxidative stress [12]. In rodent models of type 2 diabetes, systemic humanin administration improved glucose tolerance and reduced hepatic glucose output [13]. A 2020 paper in Aging Cell (N=adults across decades) showed that circulating humanin levels were 5-fold higher in centenarians than in 70-year-olds, mirroring the MOTS-c longevity association but again not establishing causality [14].

No completed Phase II or Phase III randomized controlled trial of humanin supplementation in humans appears in the published literature. An analogue called HNG (humanin with a serine-to-glycine substitution at position 14) is roughly 1,000-fold more potent in cell-based assays and is the form used in most current animal research [13]. Human pharmacokinetic data for either form are sparse. A single-dose healthy-volunteer study has not been published in a peer-reviewed journal as of this writing.

From a prescribing standpoint, humanin sits in the same regulatory category as MOTS-c: no FDA approval, no approved human dose, and no compounding pharmacy may legally supply it under current Category 2 restrictions.

FOXO4-DRI: Targeting Senescent Cells Directly

Senescent cells accumulate in tissues as organisms age, secreting a pro-inflammatory mix of cytokines, proteases, and growth factors called the senescence-associated secretory phenotype (SASP). Clearing these cells is an active therapeutic strategy. FOXO4-DRI is a D-amino-acid retro-inverso peptide designed to disrupt the interaction between the transcription factor FOXO4 and the tumor-suppressor protein p53 inside senescent cells [15].

In senescent cells, FOXO4 sequesters p53 in the nucleus, preventing the apoptosis that would normally clear the cell. FOXO4-DRI competitively binds FOXO4, releasing p53 to trigger cell death selectively in senescent cells while sparing healthy ones. A landmark 2017 Nature paper by Baar and colleagues (N=mouse cohorts) showed that FOXO4-DRI injections three times per week for 10 days reduced p21-positive senescent cells in liver, small intestine, and kidney by 60-80%, improved physical fitness on treadmill tests, restored fur density in chemotherapy-induced alopecia, and extended median lifespan in fast-aging XpdTTD/TTD mice by roughly 10 days compared with vehicle [15].

The specificity claim deserves scrutiny. The selectivity for senescent over healthy cells depends on differential FOXO4 expression. Healthy proliferating cells express lower FOXO4, so the apoptotic signal is weaker in those cells. Whether this selectivity holds across diverse human tissue types, ages, and comorbidity profiles has not been tested. No human trial of FOXO4-DRI has been published.

Cost and synthesis also matter practically. D-amino-acid peptides resist protease degradation, which extends half-life, but they are substantially more expensive to synthesize than L-amino-acid counterparts. Compounding pharmacies cannot legally supply FOXO4-DRI under current FDA rules, and no investigational new drug (IND) application for FOXO4-DRI appears in public FDA databases [16].

Regulatory Status and the FDA Compounding Framework

The FDA's authority over compounded drugs comes from Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional compounding pharmacies filling individual prescriptions; Section 503B covers outsourcing facilities producing larger batches [7]. A substance may be compounded only if it is not on the FDA's list of drugs withdrawn for safety reasons, not a copy of a commercially available drug, and meets USP standards for identity and purity.

In 2023 and 2024, the FDA moved several research peptides onto its "Category 2" list of substances under evaluation for bulk drug substance compounding. BPC-157, TB-500 (thymosin beta-4), and CJC-1295 were explicitly named. MOTS-c, Epitalon, SS-31, Humanin, and FOXO4-DRI were not included by name in published Category 2 lists as of January 2025, but the agency's general enforcement posture toward unapproved peptides has tightened considerably [7].

Physicians should inform patients of three practical points. First, obtaining any of these five peptides from online vendors without a prescription bypasses pharmacy regulation entirely, creating unknown purity and contamination risk. Second, even compounding pharmacies operating in good faith may not be able to source pharmaceutical-grade material for peptides lacking a USP monograph. Third, if a serious adverse event occurs with an unapproved compounded peptide, there is no pharmacovigilance system to capture or investigate it.

The American Academy of Anti-Aging Medicine and the Endocrine Society have both stated that prescribing unapproved peptides outside of clinical trials raises significant informed-consent obligations [17]. The Endocrine Society's 2019 position statement on compounded bioidentical hormones, while focused on hormone therapy, articulates the general principle: "Patients should be informed that compounded preparations have not undergone the rigorous testing required for FDA-approved products" [17].

Comparing the Five Peptides: Evidence Strength and Clinical Readiness

These five peptides differ substantially in how far their evidence base extends toward human clinical use. SS-31 (elamipretide) has completed Phase II trials, giving it the most mature human safety and pharmacokinetic profile of the group, even though its primary efficacy trial failed. FOXO4-DRI has the most compelling mechanistic story for senolysis but zero human trial data. Epitalon has the longest research history (50 years of Russian literature) but the weakest independent replication. MOTS-c and Humanin sit between these poles: human observational data suggest physiological relevance, and rodent intervention studies show metabolic benefit, but no human RCT exists for either.

A 2022 review in Ageing Research Reviews covering mitochondria-derived peptides (MDPs) identified 13 distinct MDPs, of which MOTS-c and Humanin have the strongest preclinical metabolic evidence [18]. The reviewers noted that the field lacks standardized bioassays to measure endogenous MDP levels consistently across labs, a methodological gap that complicates interpretation of all human observational studies.

For clinical teams advising patients who ask about these peptides, the honest summary is this: the biology is compelling, the preclinical data are sometimes striking, and the human evidence is too thin to support routine prescription. Patients with metabolic syndrome, mitochondrial disease, or accelerated biological aging may feel drawn to these options precisely because conventional treatments leave gaps. That gap is real. The solution is not to fill it with inadequately tested compounds.

Dosing: What Animal Studies Used and Why Human Doses Are Unknown

No regulatory agency has established a human dose for any of these five peptides. The following figures come from published animal studies and should not be interpreted as clinical recommendations.

MOTS-c was injected intraperitoneally at 5 mg/kg/day in the original 2015 obese-mouse studies [1]. Subcutaneous routes at 2-10 mg total dose appear in later rodent work, with dosing intervals of daily to three-times-weekly. Epitalon has been used in mouse lifespan studies at 0.1 mcg per animal per day by subcutaneous injection over 5-day cycles repeated monthly [5]. SS-31 clinical trials used intravenous infusions of 0.05 mg/kg/hour for 2 hours in cardiac patients [10]. FOXO4-DRI was injected intraperitoneally at 10 mg/kg three times weekly in the 2017 Nature mouse study [15]. Humanin and HNG animal studies use intraperitoneal or intracerebroventricular doses in the range of 4-8 mcg per animal per injection [13].

Body surface area (BSA) conversion from mouse to human using the FDA's standard 12.3 conversion factor yields rough human equivalent doses that are typically 8-12 times lower on a mg/kg basis than the mouse dose [16]. Even with that adjustment, pharmacokinetics in humans may differ profoundly due to plasma protein binding, renal clearance, and tissue distribution that have not been characterized.

Monitoring and Safety Considerations for Clinicians

Because no approved human dosing exists, physicians who prescribe these peptides in any context carry full clinical responsibility for monitoring. The following framework reflects general peptide safety principles, not peptide-specific human trial data.

Baseline labs before starting any injectable peptide protocol should include a complete metabolic panel, fasting glucose and insulin, hemoglobin A1c, CBC with differential, liver function tests, and, for peptides with proposed IGF-1 pathway involvement, a fasting IGF-1 level. Repeat labs at 8 weeks and 16 weeks allow detection of early hepatic or metabolic signal changes [19].

Injection-site reactions are the most commonly reported adverse effect in peptide trials generally. In elamipretide (SS-31) trials, injection-site erythema occurred in roughly 30% of participants receiving subcutaneous formulations [9]. Systemic reactions including nausea, fatigue, and headache were reported at rates comparable to placebo in the MMPOWER-3 trial, suggesting a modest tolerability profile at least for that peptide.

For FOXO4-DRI, the theoretical risk of off-target apoptosis in non-senescent cell populations has not been formally tested in humans. Any patient reporting unexpected tissue changes, cytopenias, or organ-function shifts while on FOXO4-DRI should have the agent stopped and a full workup initiated.

Patients should be counseled explicitly that peptide purity from non-FDA-regulated sources cannot be guaranteed. A 2022 analysis of 44 peptide products purchased from US research-chemical vendors found that 25 of 44 (57%) contained the stated peptide at less than 90% of labeled concentration, and 8 of 44 (18%) contained detectable contaminants including bacterial endotoxin [20].